Article
Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer.
Cancer research and treatment - 1 Apr 2024
Akkhasutthikun Patinya, Kaewsapsak Pornchai, Nimsamer Pattaraporn, Klomkliew Pavit, Visedthorn Suthida, Chanchaem Pragwalai, Teerapakpinyo Chinachote, Payungporn Sunchai, Luangdilok Sutima
Abstract excerpt
PURPOSE: The epidermal growth factor receptor (EGFR) mutation is a widely prevalent oncogene driver in non-small cell lung cancer (NSCLC) in East Asia. The detection of EGFR mutations is a standard biomarker test performed routinely in patients with NSCLC for the selection of targeted therapy. Here, our objective was to develop a portable new technique for detecting EGFR (19Del, T790M, and L858R) mutations based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
